"The proposed settlement comes as the U.S. Supreme Court is preparing to hear arguments in April on Bayer's assertion that the U.S. Environmental Protection Agency's approval of Roundup without a cancer warning should invalidate claims filed in state courts. That case would not be affected by the proposed settlement. But the settlement would eliminate some of the risk from an eventual Supreme Court ruling. Patients would be assured of receiving settlement money even if the Supreme Court rules in Bayer's favor."
"Germany-based Bayer, which acquired Roundup maker Monsanto in 2018, disputes the assertion that Roundup's key ingredient, glyphosate, can cause non-Hodgkin lymphoma. But the company has warned that mounting legal costs are threatening its ability to continue selling the product in U.S. agricultural markets. "Litigation uncertainly has plagued the company for years, and this settlement gives the company a road to closure," Bayer CEO Bill Anderson said Tuesday."
A proposed $7.25 billion settlement aims to resolve thousands of U.S. lawsuits alleging Roundup caused cancer and that warnings were inadequate. The settlement was filed in St. Louis Circuit Court and still requires approval. The U.S. Supreme Court will hear arguments in April on whether EPA approval without a cancer warning preempts state claims; that case would not be affected by this settlement. The agreement would secure payments for patients and limit Bayer's exposure even if the high court rules against the company. Bayer disputes glyphosate causes non-Hodgkin lymphoma and cites mounting legal costs threatening U.S. sales.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]